Abstract Number: 2550 • 2012 ACR/ARHP Annual Meeting
Clinical, Radiographic, and Immunogenic Effects After 1 Year of Tocilizumab-Based Treatment Strategy with and without Methotrexate in Rheumatoid Arthritis: The ACT-RAY Study
Background/Purpose: 24-week data from ACT-RAY comparing an add-on strategy (tocilizumab [TCZ] + methotrexate [MTX]) with a switch strategy (TCZ + placebo [PBO]) in MTX-IR patients…Abstract Number: 2551 • 2012 ACR/ARHP Annual Meeting
Validation of EULAR Primary Sjögren’s Syndrome Disease Activity and Patient Indexes
Background/Purpose: To validate the EULAR scores for assessment of primary Sjögren's Syndrome (SS): the EULAR SS Disease Activity Index (ESSDAI), the EULAR SS Patient Reported…Abstract Number: 2552 • 2012 ACR/ARHP Annual Meeting
Clinically Significant and Biopsy-Documented Renal Involvement in Primary Sjögren’s Syndrome: Clinical Presentation and Outcome
Background/Purpose: Primary Sjögren’s syndrome (pSS) may affect kidneys, causing either interstitial nephritis (IN) or glomerulonephritis (GMN). However, overt renal disease in pSS is rare and…Abstract Number: 2553 • 2012 ACR/ARHP Annual Meeting
Histological, Serological and Clinical Changes in Response to Abatacept Treatment of Sjögren’s Syndrome
Background/Purpose: To prospectively evaluate histopathologic, blood and clinical responses to abatacept treatment in patients with primary Sjögren’s syndrome (pSS). Methods: Blood, saliva and minor salivary…Abstract Number: 2554 • 2012 ACR/ARHP Annual Meeting
Tolerance and Efficacy of Rituximab in Primary Sjogren Syndrome: Final Results of a Randomized Controlled Trial
Background/Purpose: There is evidence for a critical role of B cells in the pathogenesis of pSS. Both open labelled and small controlled studies suggested the…Abstract Number: 2555 • 2012 ACR/ARHP Annual Meeting
Results of the Beliss Study, the First Open Phase 2 Study of Belimumab in Primary Sjogren’s Syndrome
Background/Purpose: The BAFF (or BLyS) cytokine plays a key role in pathogenesis of primary Sjogren’s syndrome (pSS). Belimumab, the first biological treatment inhibiting soluble BAFF,…Abstract Number: 2556 • 2012 ACR/ARHP Annual Meeting
Allogenic Mesenchymal Stem Cells Transplantation Alleviates Clinical Sjögren’s Syndrome
Background/Purpose: Sjögren's syndrome (SS) is a systemic autoimmune disease that is characterized by dry mouth and dry eyes. Currently, treatment of SS is difficult and…Abstract Number: 2557 • 2012 ACR/ARHP Annual Meeting
Ustekinumab in Active Psoriatic Arthritis Including Patients Previously Treated with Anti-TNF Agents: Results of a Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Ustekinumab in active psoriatic arthritis including patients previously treated with anti-TNF agents: Results of a Phase 3, multicenter, double-blind, placebo-controlled studyBackground/Purpose: Assess efficacy & safety…Abstract Number: 2558 • 2012 ACR/ARHP Annual Meeting
Clinical Response, Drug Survival and Predictors Thereof Among 548 Switchers of Tumor Necrosis Factor Alpha Inhibitor Therapy in Psoriatic Arthritis. Results From the Danish Nationwide Danbio Registry
Background/Purpose: Treatment with tumor-necrosis-factor-alpha inhibitors (TNFi) has improved the outcome in patients with psoriatic arthritis (PsA) who have failed treatment with synthetic disease modifying antirheumatic…Abstract Number: 2559 • 2012 ACR/ARHP Annual Meeting
Mortality in Patients with Psoriatic Arthritis Compared to Patients with Rheumatoid Arthritis, Psoriasis Alone, and the General Population
Background/Purpose: Conflicting reports of the mortality risk among patients with psoriatic arthritis (PsA) exist in the literature, however excess mortality has been presumed given the…Abstract Number: 2560 • 2012 ACR/ARHP Annual Meeting
Response and Drug Survival of 1st TNF-Inhibitor in 440 Patients with Psoriatic Arthritis – What Is the Role of Co-Medication with Methotrexate?
Background/Purpose: It is well established that methotrexate (MTX) co-medication improves efficacy of TNF-inhibitors (TNFi) in rheumatoid arthritis, while in ankylosing spondylitis it is widely accepted…Abstract Number: 2561 • 2012 ACR/ARHP Annual Meeting
Switching Between TNF-Inhibitors in Psoriatic Arthritis: Data From the NOR-DMARD Study
Background/Purpose: Although TNF-inhibitors (TNFi) have proven efficacy in psoriatic arthritis (PsA), some patients do not respond to or do not tolerate their first TNFi. The…Abstract Number: 2562 • 2012 ACR/ARHP Annual Meeting
Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-Blind, Placebo-Controlled Psummit I Study
Ustekinumab in Patients with Active Psoriatic Arthritis: Results of the Phase 3, Multicenter, Double-blind, Placebo-Controlled PSUMMIT I StudyBackground/Purpose: To assess efficacy and safety of ustekinumab…Abstract Number: 2563 • 2012 ACR/ARHP Annual Meeting
Factors Associated with Major Cardiovascular Events in Patients with Primary Systemic Necrotizing Vasculitides: Results of a Longitudinal Long-Term Follow-up Study
Background/Purpose: Primary systemic necrotizing vasculitides (SNV) were shown to be associated with more frequent subclinical atherosclerosis, independently of cardiovascular (CV) risk factors and C-reactive protein…Abstract Number: 2564 • 2012 ACR/ARHP Annual Meeting
A Risk Score for Predicting Short-Term Incidence of Death or Relapse in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Background/Purpose: Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV), combining granulomatosis with polyangiitis (GPA) and microscopic polyangiitis (MPA), is associated with a substantial risk of relapse or…
ACR Meeting Abstracts